What Poly Pharmaceuticals does

Poly Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company founded in 1980 in Owens Cross Roads, Alabama, by a group of pharmacists. The company develops, manufactures, markets, and distributes branded, generic, and over-the-counter therapeutic products focused on four therapeutic areas: cough and cold, pain management, urological health, and allergy and sinusitis. Its portfolio consists of seven core product lines — Alahist, Deconex, Duraflu, Poly Hist, Poly Tussin, Poly Vent, and Udamin SP — available in tablet and liquid formulations, alongside co-promoted products including Kristalose 10mg and 20mg.

The company generates revenue through the manufacture and sale of these pharmaceutical products distributed to physicians, pharmacies, and wholesale distributors throughout the United States. Its go-to-market motion is sales-led, relying on a dedicated sales force that engages healthcare practitioners directly; the corporate website supplements this with sample-request functionality gated behind DEA and NPI credentials. Products reach patients via retail pharmacy channels and wholesale distribution networks across domestic markets. Pricing is not publicly disclosed.

Poly operates with a small team (reported 1–10 employees) and pursues portfolio expansion primarily through strategic business alliances, in-licensing arrangements, and targeted acquisitions rather than large-scale internal R&D. The company is registered as a corporation in Alabama, has an active website and careers channel, and continues to launch new products annually under its existing brand portfolio and via co-promotion agreements. <parameter name="company_description_short">

Name

Poly Pharmaceuticals

Legal name

Poly Pharmaceuticals, Inc.

Website

https://polypharm.net

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

1–10 employees

Short description

Poly Pharmaceuticals is a privately held, Alabama-based specialty pharmaceutical company founded in 1980 that manufactures and distributes branded, generic, and OTC therapeutics for cough/cold, allergy, pain, and urological health to physicians, pharmacies, and wholesalers across the United States.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Nephrology & Urology Pharmaceuticals (HLAIAAAM)

Keywords

• Specialty pharmaceuticals
• Cough cold medications
• Generic drug manufacturing
• OTC pharmaceuticals
• Prescription therapeutics

Headquarters

HQ city

Owens Cross Roads

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated through the manufacture, marketing, and distribution of branded, generic, and OTC pharmaceutical products to healthcare providers, pharmacies, and wholesalers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels1 record

Core offering

Poly Pharmaceuticals is an independent specialty pharmaceutical company that manufactures, markets, and distributes branded, generic, and OTC therapeutic products in tablet and liquid formulations. Its portfolio targets four therapeutic areas — cough and cold, pain management, urological health, and allergy/sinusitis — and is organized into seven core product lines (Alahist, Deconex, Duraflu, Poly Hist, Poly Tussin, Poly Vent, Udamin SP) plus co-promoted Kristalose products. Products are sold to physicians, pharmacies, and wholesalers throughout the United States.

Product overview

Poly Pharmaceuticals is an independent specialty pharmaceutical company that manufactures, markets, and distributes branded, generic, and OTC therapeutic products. The company operates as a single product portfolio rather than a unified platform architecture, organized into multiple product lines targeting cough and cold, pain management, urological health, and allergy and sinusitis conditions. Their product portfolio includes seven core product lines—Alahist, Deconex, Duraflu, Poly Hist, Poly Tussin, Poly Vent, and Udamin SP—along with co-promoted products (Kristalose 10mg and 20mg). Products are distributed in tablet and liquid formulations to physicians, pharmacies, and wholesalers throughout the United States.

Differentiator

Problem solved

Functional benefit

Brands

• Alahist: Product line including Alahist CF, Alahist IR, Alahist PE, Alahist DM
• Deconex
• Duraflu
• Poly Hist
• Poly Tussin
• Poly Vent
• Udamin SP

Products and services

• Alahist Product line of cough and cold medications available in tablet form (Alahist CF, Alahist IR, Alahist PE) and liquid form (Alahist DM), distributed to physicians, pharmacies, and wholesalers across the United States.
• Deconex Product line of decongestant medications available in tablet form (Deconex IR, Deconex DMX), distributed to physicians, pharmacies, and wholesalers in the United States.
• Duraflu Tablet-form cold medication product line distributed to physicians, pharmacies, and wholesalers in the United States.
• Poly Hist Product line of antihistamine/cold medications available in multiple formulations (Poly-Hist Forte, Poly-Hist DM, Poly-Hist PD), distributed to physicians, pharmacies, and wholesalers in the United States.
• Poly Tussin Liquid cough suppressant product line (Polytussin DM) distributed to physicians, pharmacies, and wholesalers in the United States.
• Poly Vent Product line of respiratory/cold medications available in tablet form (Poly Vent IR, Poly Vent DM), distributed to physicians, pharmacies, and wholesalers in the United States.
• Udamin SP Urological health product line distributed to physicians, pharmacies, and wholesalers in the United States.
• Kristalose Co-promoted prescription laxative product available in 10mg and 20mg dosages, distributed to physicians, pharmacies, and wholesalers in the United States.

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Strategic Business AlliancescoreStrategic or Co-development PartnerPoly Pharmaceuticals brings new products to market each year through strategic business alliances, acquisitions, product development, and licensing arrangements. These partnerships support the company's product portfolio expansion in therapeutic areas including cough/cold, pain management, urological health, and allergy/sinusitis.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• ANI Pharmaceuticals: Larger specialty/generic pharma with U.S. manufacturing and broad therapeutic reach including urology — broader portfolio but overlapping channels and customer base with Poly.
• Lannett Company: Diversified U.S. generic and specialty pharma distributing through wholesalers and pharmacies — same B2B distribution channels and customer types as Poly, though at significantly larger scale.
• Church & Dwight: Major consumer-health/OTC company with leading brands across cough/cold, allergy, and pain — competes head-on with Poly's core OTC categories despite vastly different scale.
• Padagis: Specialty generics and OTC pharmaceutical company with strong cough/cold and respiratory franchises (e.g., historically a major player in cough/cold remedies) — directly competes in Poly's core therapeutic categories and share the same pharmacy/wholesaler channels.
• Haleon: Global consumer-health company owning major OTC brands in cough/cold, allergy, and pain management — competes aggressively in the same shelf categories where Poly's products are dispensed.

Direct peers

• Almatica Pharma: Specialty pharmaceutical company focused on branded prescription products in CNS, women's health, and urology — comparable scale, sales-led distribution model, and therapeutic categories.
• Aytu BioPharma: Specialty pharma commercializing prescription and consumer health products with a dedicated sales force in urology, pediatrics, and primary care — similar channel structure and therapeutic-area strategy to Poly.
• Avion Pharmaceuticals: Independent U.S. specialty pharma focused on women's health, urology, and primary care, distributing through physicians, pharmacies, and wholesalers — directly comparable business model and therapeutic overlap with Poly (notably urology).
• Vertical Pharmaceuticals (a Trigen Holdings company): Small U.S. specialty pharmaceutical company marketing branded prescription and OTC products through physician and pharmacy channels — closely mirrors Poly's specialty distribution model and therapeutic-area breadth.

Emerging players

• Founded Pharmaceuticals (Innocutis/Foundrax): Smaller specialty pharma distributing niche branded and prescription products via physician/pharmacy channels with similar lean operating profile to Poly.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat1 record

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/poly-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Poly Pharmaceuticals